ArticleCureus2026
The Persistent Gap in Mass Drug Administration Uptake Among Known Microfilaria-Positive Individuals in India's Lymphatic Filariasis Elimination Program: A Call for Strengthened Follow-Up Strategies.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India's lymphatic filariasis elimination program has achieved high mass drug administration (MDA) coverage and substantial reductions in transmission across endemic districts. As the program transitions toward transmission assessment surveys (TAS) and post-MDA surveillance, the strategic focus is shifting from expanding coverage to sustaining verified interruption of transmission. However, reliance solely on aggregate coverage metrics may overlook an important endgame vulnerability: incomplete longitudinal follow-up of individuals identified as microfilaria (Mf) positive or filarial test strip (FTS) positive during surveillance activities. Although defined epidemiologic thresholds (microfilaremia <1% or antigenemia <2% in young children) guide decisions to stop MDA, achieving these benchmarks does not necessarily ensure that all previously identified infected individuals have cleared infection. In low-prevalence settings, even small numbers of untreated or inadequately treated individuals may sustain localized transmission. Strengthening case-based registries, treatment verification mechanisms, and structured follow-up of confirmed positives can enhance epidemiologic confidence in validated elimination and reduce the risk of recrudescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.